Find a study
Browse recruiting studies near you — free to check, always your choice.
34 studies
Recruiting now, in plain language. Every study is watched over by an independent ethics board.
- Depression
The Role of mGluR5 in CBT-I
Testing how a brain receptor may affect CBT-I for insomnia in people with depression
📍 Stony Brook University: Dept of Psychiatry · Stony Brook, NY · Get directions →
This is mechanistic clinical trial that evaluates the role of one of the glutamate receptors (mGluR5) in cognitive behavioral therapy for insomnia (CBT-I) as a common pathway in improving sleep and depression.
- Depression
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
Testing brain scan and EEG measures to predict response to depression treatment
📍 Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600 · Austin, TX · Get directions →
The purpose of the study is to identify brain biomarkers and characteristics that predict individual responses to treatment of major depression with the antidepressant drug sertraline (tradename Zoloft), a common selective serotonin reuptake inhibitor (SSRI) antidepressant. Our central hypothesis is that brain activity and connections jointly measured with functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) will be able to predict an individual's response to sertraline treatment.
- Depression
Serotonin-norepinephrine Reuptake Inhibitor in Prophylaxis of Depression Following Fragility Fractures
Testing how feasible it is to prescribe antidepressants after fragility fractures in adults 50 and
📍 Wake Forest University Health Sciences · Winston-Salem, NC · Get directions →
The goal of this pilot study is to learn about the feasibility about prescribing anti-depressants at discharge in patients aged 50 years and older with a lower extremity fragility fracture. The main questions it aims to answer are: * What are the obstacles to enrolling patients and prescribing anti-depressants among older adults?
- Depression
Dopaminergic Therapy for Anhedonia - 2
Testing an 8-week treatment using L-DOPA for depression with low pleasure and high inflammation
📍 Emory University Hospital · Atlanta, GA · Get directions →
The purpose of this 8-week, double-blind, placebo-controlled, study is to explore new treatment options for people with depression who have high inflammation and anhedonia. Seventy male and female participants with depression, between 25-55 years of age, with higher levels of inflammation and anhedonia will be randomized to receive L-DOPA or matched placebo over 8 weeks.
- Rheumatoid arthritis
Oral Versus Intramuscular Steroid Use to Control Rheumatoid Arthritis Flares
Comparing pills versus shots of steroids to control rheumatoid arthritis flares
📍 Sunnybrook Health Sciences Centre · Toronto, Ontario · Get directions →
People living with rheumatoid arthritis (RA) often experience flares-periods where their symptoms suddenly get worse. These flares can cause significant pain, make it harder to move and do daily activities, and lower overall quality of life.
- Depression
Identifying and Treating Depression in the Orthopaedic Trauma Population
Testing how orthopedic trauma teams can screen for depression and treat it with medication
📍 Wake Forest University Health Sciences · Winston-Salem, NC · Get directions →
The goal of this trial is to pilot a way for orthopaedic surgeons to safely screen for depression and provide treatment for depression with medication. The main questions it aims to answer are: 1.
- Parkinson's disease
A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
Testing a carbidopa and levodopa extended-release capsule in people with Parkinson’s
📍 Barrow Neurological Institute · Phoenix, AZ · +26 more US sites · Get directions →
The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).
- Rheumatoid arthritis
Advanced Therapeutics in Rheumatoid Arthritis (RA)
Tracking how long two rheumatoid arthritis treatments are kept in adults
📍 Rheumatology Clinic, St. Joseph's Health Care · London, Ontario · Get directions →
This study will evaluate the retention rates of two advanced therapies, Tumour Necrosis Factor (TNF) and Janus kinase inhibitor (JAK) in the treatment of adults with Rheumatoid Arthritis (RA) over a two year period. It will also examine the ability to embed a clinical trial in a clinical situation using an electronic medical record (EMR).
- Depression
Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)
Comparing best step-by-step treatments for depression with anxiety
📍 University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience · Cincinnati, OH · Get directions →
Acute, double-blind, adaptively randomized treatment with duloxetine or escitalopram, followed by double-blind, randomized adjunctive treatment with clonazepam or pregabalin for persistent symptoms.
- Depression
Neural Circuit Effects of Ketamine in Depression
Testing how ketamine affects brain activity and depression symptoms
📍 Icahn School of Medicine at Mount Sinai · New York, NY · Get directions →
This project is designed to examine the role of the subgenual anterior cingulate cortex (sgACC) in anhedonia and anxiety in humans with depression, as well as the acute and sustained effects of ketamine on agACC activation and depression symptoms.
- Depression
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
Comparing a drug called AXS-05 with bupropion to prevent depression relapse
📍 Clinical Research Site · Bellflower, CA · +39 more US sites · Get directions →
This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder (MDD) who have responded to treatment with AXS-05.
- DepressionDementia / Alzheimer's
Aβ Dynamics in LLMD
Testing how treating depression may change brain markers linked to Alzheimer’s
📍 NYU Langone Health · New York, NY · +1 more US site · Get directions →
This study will examine the biological factors that may modulate the relationship between depression and the development of Alzheimer's disease (AD). Since the direction of causation between depression and the biological factors associated with AD is unknown, the only way to understand cause and associated risk is to treat the depressive symptoms and examine the effects on AD biomarkers.
- Depression
Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)
Testing a biomarker prediction tool to forecast depression treatment outcomes
📍 University of Calgary · Calgary, Alberta · Get directions →
This is a study that will test a predictive biomarker algorithm based on results from a previous study. The goal of this study is to integrate clinical, imaging, EEG, and molecular data across 8 sites to predict treatment outcome for patients experiencing a major depressive episode (MDE).
- Parkinson's disease
Cortical Electrophysiology of Response Inhibition in Parkinson's Disease
Studying how deep brain stimulation in Parkinson’s affects brain control of stopping actions
📍 Emory University Hospital · Atlanta, GA · +1 more US site · Get directions →
Patients with Parkinson's Disease will be studied before, during, and after a deep brain stimulation implantation procedure to see if the stimulation location and the size of the electrical field produced by subthalamic nucleus (STN) DBS determine the degree to which DBS engages circuits that involve prefrontal cortex executive functions, and therefore have a direct impact on the patient's ability to inhibit actions.
- Depression
Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression
Studying how menstrual hormone changes affect mood and reward in women with depression
📍 University of North Carolina, Chapel Hill · Chapel Hill, NC · Get directions →
The goal of this clinical trial is to learn how hormonal changes over the menstrual cycle affect mood symptoms in reproductive-aged women with depression that worsens during the premenstrual period. The main questions it aims to answer are: --How do fluctuations in estradiol and progesterone across the menstrual cycle affect the ability to experience pleasure and the neural sensitivity to reward in hormone-sensitive, depressed women?
- Depression
PET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine.
Testing PET brain scans to study how nicotine may affect depression
📍 Stony Brook University: Dept of Psychiatry · Stony Brook, NY · Get directions →
In the brain, certain nerve cells communicate using a chemical called acetylcholine. Acetylcholine is thought to be important for several functions including mood, memory and wakefulness.
- Depression
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Testing valbenazine in adults with tardive dyskinesia who still have symptoms
📍 Neurocrine Clinical Site · Bryant, AR · +21 more US sites · Get directions →
This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.
- Parkinson's disease
BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease
Testing a new long-acting levodopa dose to improve “on” time in Parkinson’s
📍 Cleveland Clinic · Cleveland, OH · Get directions →
The purpose of this study is to evaluate the effect of IPX203 (Crexont®) - the newest extended-release levodopa formulation - on the duration and quality of good on time, using a wearable device to monitor symptoms. 'Good on time' refers to a period (minutes to hours) when a patient experiences optimal symptom control due to effective medication and has better overall functioning without troublesome dyskinesias.
- Depression
Esketamine With or Without Integration Therapy for Treatment-Resistant Depression
Testing whether nasal esketamine with or without therapy helps adults with depression that hasn’t
📍 Pravan Foundation · San Juan, · Get directions →
This study will explore the effects of esketamine (Spravato®), an FDA-approved nasal spray, on adults diagnosed with treatment-resistant depression (TRD). All participants will receive esketamine as prescribed by a healthcare professional in a clinical setting.
- Depression
Personalized Indications for CBT and Antidepressants in Treating Depression
Testing how cognitive-behavioral therapy and antidepressant use can be matched for people with
📍 Nova Scotia Health Authority · Halifax, Nova Scotia · Get directions →
Depression currently affects close to 2 million Canadians and is the leading cause of disability worldwide. Pharmacological treatments (antidepressant medication) and psychological treatments such as cognitive-behavioural therapy are available for depression, but the majority of those who receive treatment have an unsatisfactory response.
- Depression
ECT with Ketamine Anesthesia Vs High Intensity Ketamine with ECT Rescue for Treatment-Resistant Depression
Testing whether high-intensity ketamine with ECT rescue works better than ECT with ketamine
📍 Royal University Hospital · Saskatoon, Saskatchewan · Get directions →
To determine if an high intensity ketamine with ECT rescue (HIKER) approach for treatment resistant depression will: 1) reduce patient suffering by hastening disease remission, 2) have fewer side effects, 3) reduce the need for ECT, and 4) be preferred by most patients. Half of participants will be randomized to the HIKER arm and receive high intensity ketamine treatment for eight consecutive days, and the other half will be assigned to the ECT with ketamine anesthesia (EAST) arm and receive 8 ECT treatments (2-3 treatment/week)
- Parkinson's disease
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
Comparing treatments to see which works better for hallucinations in Parkinson’s disease
📍 Southern Arizona VA Health Care System, Tucson, AZ · Tucson, AZ · +23 more US sites · Get directions →
Patients with Parkinson's disease (PD) sometimes experience symptoms affecting their movement, such as slowness, tremor, stiffness, and balance or walking problems. Many patients also have other symptoms not related to movement, called non-motor symptoms, which may affect one's mood or emotions, memory or thinking, or cause one to see or hear things that aren't real (hallucinations) or believe things that aren't true (delusions).
- Depression
RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)
Testing whether RNA changes predict response to depression treatment
📍 Mayo Clinic in Rochester · Rochester, MN · Get directions →
The purpose of this research is to understand how changes in RNA editing relate to treatment response in unipolar and bipolar depression.
- Dementia / Alzheimer'sParkinson's disease
Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia
Studying how nerve cell loss affects thinking ups and downs in Lewy body dementia
📍 Virginia Commonwealth University · Richmond, VA · Get directions →
The proposed study aims to address the critical gaps in understanding the mechanisms of CF (Cognitive Fluctuations) by leveraging recently emerged molecular biomarkers, advanced neuroimaging techniques to assess measures of cholinergic degeneration, and synchronous EEG and assessments of attention. One of the overarching innovations of study is combining all of these assessments into one integrated research plan
- Depression
Establishing Mobile Transcranial Magnetic Stimulation
Testing a portable brain-stimulation device for treating depression
📍 Medical Univerity of South Carolina · Charleston, SC · Get directions →
In this pilot study, investigators propose to design and create a portable TMS unit, in a van, and then test out delivering TMS in three different locations in South Carolina, all affiliated with MUSC and within 2-hours driving from Charleston, SC. This study would test out this new delivery mode, and provide valuable feasibility, safety, and efficacy lessons for later refinement and potential widespread adoption of mobile TMS as a treatment option, both in our state and across the US.
- DepressionAnxiety
Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
Studying brain circuits for threat sensitivity in people with anxiety and depression
📍 Laureate Institute for Brain Research · Tulsa, OK · Get directions →
This mechanistic study uses an anti anxiety drug and brain imaging to study the threat processing system and associated brain circuits in people with depression, anxiety disorders and comorbid depression and anxiety disorders. In a double blind, placebo controlled crossover design, up to 65 individuals will be recruited who will have a diagnosis of major depressive disorder (MDD) and at least one anxiety disorder (AD) (AD-MDD group), up to 65 participants will have a diagnosis of MDD and no diagnosis of an AD and up to 65 participants will have no diagnosis of MDD and a diagnosis of at least one AD will be enrolled to participate in an two session study to obtain 150 completers (50 per group).
- Parkinson's disease
Personalized Real-Time DBS and PD Mechanisms
Studying how closed-loop deep brain stimulation and levodopa affect Parkinson’s motor symptoms
📍 Cleveland Clinic · Cleveland, OH · Get directions →
A prospective cohort of patients scheduled to undergo deep brain stimulation (DBS) implantation surgery for the treatment of Parkinson's disease as per standard of care will be invited to participate in this study. This mechanistic study is aimed at better understanding the role of basal ganglia beta band (11-35 Hz) oscillations and resonance in the manifestation of Parkinson's disease (PD) motor signs using closed-loop electrical neurostimulation, levodopa medication, and computational modeling.
- DepressionAnxiety
Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)
Testing antidepressant treatment for anxious teens with anxiety and depression
📍 University of Cincinnati · Cincinnati, OH · Get directions →
Acute, double-blind, adaptively randomized treatment with duloxetine or escitalopram, followed by open-label naturalistic follow-up.
- Depression
Buspirone and Melatonin for Depression Following Traumatic Brain Injury
Testing buspirone and melatonin for depression after a traumatic brain injury
📍 Massachusetts General Hospital · Boston, MA · +1 more US site · Get directions →
Traumatic brain injuries (TBIs) are common. Post-TBI depression is associated with anxiety, aggression, fatigue, distractibility, anger, irritability, and rumination.
- Depression
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
Testing whether estradiol affects depression symptoms tied to reward
📍 University of North Carolina at Chapel Hill · Chapel Hill, NC · Get directions →
This proposal will examine the effects of estradiol administration on perimenopausal-onset (PO) anhedonia and psychosis symptoms as well as on brain function using simultaneous positron emission tomography and functional magnetic resonance imaging (PET-MR).
- Parkinson's disease
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
Measuring serotonin 2A brain receptor activity in people with Parkinson’s
📍 Vanderbilt University Medical Center · Nashville, TN · Get directions →
It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age/sex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-\[18F\]MH.MZ in both populations.
- Depression
Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
Testing whether ketamine or esketamine helps prevent suicide in people with depression
📍 Massachusetts General Hospital · Boston, MA · Get directions →
The study will consist of a 24-week-long trial examining outcomes in patients with Major Depressive Disorder and suicidal ideation who will receive intravenous (IV) ketamine and intranasal (IN) esketamine, compared to a large sample of matched historical controls. Patients will be recruited from an inpatient psychiatric unit.
- Dementia / Alzheimer'sParkinson's disease
Comparing Antipsychotic Medications in LBD Over Time
Comparing medicines to see which works better for hallucinations or delusions in Lewy body disease
📍 University Health System · San Antonio, TX · +1 more US site · Get directions →
The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or delusions due to Parkinson's disease (PD) or dementia with Lewy bodies (DLB) - collectively referred to as Lewy body disease (LBD).
- Depression
Ketamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients
Testing ketamine given during surgery to improve pain and depression after serious bone injury
📍 Texas Tech University Health Sciences Center Lubbock · Lubbock, TX · +1 more US site · Get directions →
The goal of this clinical trial is to learn if ketamine, given during surgery, can help improve recovery for adults with serious orthopedic trauma. The study will test whether ketamine reduces pain, lowers the need for opioids, and improves mental health outcomes like depression and post-traumatic stress disorder (PTSD).